Headline
The latest stories from AHA Today.
Drug maker AstraZeneca said it will seek an emergency use authorization for its AZD1222 vaccine candidate for SARS-CoV-2 following positive high-level results from an interim analysis of ongoing clinical trials.
Learn how Rogers Behavioral Health, based in Oconomowoc, Wisc., is using the LEAN process improvement methodology to optimize value for patients during the pandemic.
Hospital outpatient departments, critical access hospitals, rural health clinics and other eligible providers may apply through Jan. 3 to participate in the Value in Opioid Use Disorder Treatment demonstration.
The Centers for Medicare & Medicaid Services has selected 916 primary care practices and 37 regional health plan partners to participate in the Primary Care First model beginning Jan. 1.
The Centers for Medicare & Medicaid Services will host a Dec. 8 webinar on its final rule requiring hospitals to disclose payer-specific negotiated rates effective Jan. 1.
The Trump administration announced two actions that it claims will lower prescription drug prices.
The Department of Health and Human Services released its final rules with changes to the Stark Law and Anti-kickback statute. AHA members will receive a Special Bulletin highlighting key changes.
Sarah Krevans, president and CEO of Sutter Health, joined AHA Board Chair Melinda Estes, M.D., yesterday to discuss how hospitals can move from relief, recovery, and rebuilding to reimagining and innovation.
The Department of Health and Human Services recently distributed 27,000 portable COVID-19 molecular test kits, which Alaska, Florida, Louisiana, New Jersey, and Texas can use at the point of care to verify antigen test results within 20 minutes.
The Food and Drug Administration authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.